Anavex Life Sciences Corp.
AVXL
$4.18
-$0.02-0.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.19% | 25.79% | -18.28% | 7.56% | -4.23% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.25% | -13.95% | 198.41% | -29.49% | -0.82% |
| Change in Net Operating Assets | -3.16% | 29.53% | -191.11% | 288.52% | -171.42% |
| Cash from Operations | 16.89% | 30.97% | -112.84% | 51.68% | -82.04% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 247.19% | 8,691.60% | -86.03% | 20.34% | 695.51% |
| Repurchase of Common Stock | -- | 80.33% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 262.61% | 567.43% | -351.53% | 20.34% | 695.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,964.54% | 109.67% | -191.91% | 56.15% | -73.73% |